Cargando…

Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS

OBJECTIVE: We examined the effect of glatiramer acetate (GA) on B-cell maturation, differentiation, and antigen presentation in MS and experimental autoimmune encephalomyelitis (EAE). METHODS: A cross-sectional study of blood samples from 20 GA-treated and 18 untreated patients with MS was performed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Häusler, Darius, Hajiyeva, Zivar, Traub, Jan W., Zamvil, Scott S., Lalive, Patrice H., Brück, Wolfgang, Weber, Martin S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136047/ https://www.ncbi.nlm.nih.gov/pubmed/32184341 http://dx.doi.org/10.1212/NXI.0000000000000698

Ejemplares similares

Glatiramer acetate treatment negatively regulates type I interferon signaling
por: Molnarfi, Nicolas, et al.
Publicado: (2015)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis
por: Nissimov, Nitzan, et al.
Publicado: (2020)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen
por: Kinzel, Silke, et al.
Publicado: (2016)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
por: Novotna, Bronislava, et al.
Publicado: (2014)

EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS
por: Guerrera, Gisella, et al.
Publicado: (2020)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
por: Arnold, Douglas L., et al.
Publicado: (2013)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
por: De Riccardis, Lidia, et al.
Publicado: (2016)

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
por: D’Alessandro, Josephine, et al.
Publicado: (2017)

Process signatures in glatiramer acetate synthesis: structural and functional relationships
por: Campos-García, Víctor R., et al.
Publicado: (2017)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
por: Vlahova, Lyubomira, et al.
Publicado: (2021)

Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients
por: Lee, Andrew, et al.
Publicado: (2017)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
por: Towfic, Fadi, et al.
Publicado: (2014)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Publicado: (2015)

Restoration of Axon Conduction and Motor Deficits by Therapeutic Treatment with Glatiramer Acetate
por: Moore, Spencer, et al.
Publicado: (2014)

Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
por: Davis, Mat D., et al.
Publicado: (2017)

Glatiramer acetate does not protect from acute ischemic stroke in mice
por: Kraft, Peter, et al.
Publicado: (2014)

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis
por: Kuerten, Stefanie, et al.
Publicado: (2018)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis
por: Melnikov, Mikhail, et al.
Publicado: (2020)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
por: Mirabella, Massimiliano, et al.
Publicado: (2022)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
por: Koc, Ümmügülsüm, et al.
Publicado: (2023)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
por: Caporro, Matteo, et al.
Publicado: (2014)

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
por: Häusler, Darius, et al.
Publicado: (2018)

T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment
por: Chen, Li, et al.
Publicado: (2015)

Glatiramer acetate attenuates the activation of CD4(+) T cells by modulating STAT1 and −3 signaling in glia
por: Ahn, Ye-Hyeon, et al.
Publicado: (2017)

The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients
por: Rovituso, Damiano M., et al.
Publicado: (2015)

Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression?
por: Geladaris, Anastasia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rphi4uhh5trp5ucdiaqe8f02ee